The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Very Elderly: the TAHOC Study
Overview
- Phase
- Not Applicable
- Intervention
- Antihypertensive Agents
- Conditions
- Neurocognitive Disorders
- Sponsor
- Central Hospital, Nancy, France
- Enrollment
- 353
- Locations
- 1
- Primary Endpoint
- number of antihypertensive agents
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Neurocognitive disorders and hypertension occur commonly with aging. While, by definition, older adults are at high cardiovascular risk, there is no guideline exist currently on blood pressure management of elderly hypertension. However, studies have shown that in aging adults, high blood pressure helps prevent against cognitive decline, and low blood pressure on antihypertensive drugs could accelerate it. This study aims at investigating if pharmacological treatment of hypertension in the very elderly is influenced by presence and severity of neurocognitive disorders. Our research hypothesis is that the drug management of hypertension in patients 80 years of age or older more is all the less aggressive as the neurocognitive disorders are advanced.
Investigators
Pr Athanase BENETOS
principal investigator
Central Hospital, Nancy, France
Eligibility Criteria
Inclusion Criteria
- •to be 80 years of age
- •with history of hypertension and/or on hypertensive drug(s)
Exclusion Criteria
- •legal protection measure.
Arms & Interventions
control group
absence of neurocognitive disorder (ND), Mini-Mental State Examination (MMSE) from 27 to 30 inclusive
Intervention: Antihypertensive Agents
mild neurocognitive disorder
MMSE from 21 to 26 inclusive
Intervention: Antihypertensive Agents
moderate neurocognitive disorder
MMSE from 11 to 20 inclusive
Intervention: Antihypertensive Agents
severe neurocognitive disorder
MMSE less than or equal to 10
Intervention: Antihypertensive Agents
Outcomes
Primary Outcomes
number of antihypertensive agents
Time Frame: during inclusion
among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker
Secondary Outcomes
- orthostatic hypotension(during inclusion)
- class of antihypertensive medications(during inclusion)
- systolic and diastolic blood pressure(during inclusion)